CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Slow Release DHEAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05623059
NCT05623059Phase 2Completed
CompareCT.gov

Phase IIa Clinical Trial to Evaluate Pharmacokinetics and Safety of Slow Release DHEA

Indiana University·interventional·Posted Nov 21, 2022·Updated Jul 10, 2025

In Brief

A Phase 2 clinical trial evaluating Slow Release DHEA for Asthma and Genotype. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

This is a study to look at pharmacokinetic levels of different doses of slow release DHEA in subjects with asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Genotype
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedNov 21, 2022
Enrollment StartMar 3, 2023
Primary CompletionApr 24, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.6 years ago

Interventions

Slow Release DHEAdrug

DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.